MSFT   184.29 (-0.34%)
FB   230.86 (-0.80%)
AMZN   2,470.18 (-0.09%)
CGC   16.80 (+4.09%)
BABA   217.86 (+1.65%)
MU   48.23 (+3.01%)
GE   7.29 (+3.40%)
AMD   52.55 (-1.85%)
T   31.42 (+1.39%)
ACB   14.59 (+0.41%)
F   6.08 (+3.05%)
DIS   121.38 (+2.21%)
NFLX   421.25 (-1.42%)
BAC   26.03 (+4.79%)
BA   165.15 (+7.72%)
MSFT   184.29 (-0.34%)
FB   230.86 (-0.80%)
AMZN   2,470.18 (-0.09%)
CGC   16.80 (+4.09%)
BABA   217.86 (+1.65%)
MU   48.23 (+3.01%)
GE   7.29 (+3.40%)
AMD   52.55 (-1.85%)
T   31.42 (+1.39%)
ACB   14.59 (+0.41%)
F   6.08 (+3.05%)
DIS   121.38 (+2.21%)
NFLX   421.25 (-1.42%)
BAC   26.03 (+4.79%)
BA   165.15 (+7.72%)
MSFT   184.29 (-0.34%)
FB   230.86 (-0.80%)
AMZN   2,470.18 (-0.09%)
CGC   16.80 (+4.09%)
BABA   217.86 (+1.65%)
MU   48.23 (+3.01%)
GE   7.29 (+3.40%)
AMD   52.55 (-1.85%)
T   31.42 (+1.39%)
ACB   14.59 (+0.41%)
F   6.08 (+3.05%)
DIS   121.38 (+2.21%)
NFLX   421.25 (-1.42%)
BAC   26.03 (+4.79%)
BA   165.15 (+7.72%)
MSFT   184.29 (-0.34%)
FB   230.86 (-0.80%)
AMZN   2,470.18 (-0.09%)
CGC   16.80 (+4.09%)
BABA   217.86 (+1.65%)
MU   48.23 (+3.01%)
GE   7.29 (+3.40%)
AMD   52.55 (-1.85%)
T   31.42 (+1.39%)
ACB   14.59 (+0.41%)
F   6.08 (+3.05%)
DIS   121.38 (+2.21%)
NFLX   421.25 (-1.42%)
BAC   26.03 (+4.79%)
BA   165.15 (+7.72%)
Log in

NASDAQ:GTHXG1 Therapeutics Stock Price, Forecast & News

$17.91
-0.74 (-3.97 %)
(As of 06/3/2020 11:23 AM ET)
Add
Compare
Today's Range
$17.85
Now: $17.91
$18.90
50-Day Range
$12.29
MA: $14.85
$18.13
52-Week Range
$8.80
Now: $17.91
$41.80
Volume10,309 shs
Average Volume542,105 shs
Market Capitalization$675.92 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Read More
G1 Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GTHX
CUSIPN/A
Phone919-213-9835

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.80 per share

Profitability

Net Income$-122,450,000.00

Miscellaneous

Employees84
Market Cap$675.92 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.

G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

How has G1 Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GTHX shares have increased by 23.6% and is now trading at $17.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of G1 Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for G1 Therapeutics.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for G1 Therapeutics.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics Inc (NASDAQ:GTHX) released its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.98) by $0.16. View G1 Therapeutics' earnings history.

What price target have analysts set for GTHX?

7 analysts have issued twelve-month price targets for G1 Therapeutics' stock. Their forecasts range from $23.00 to $82.00. On average, they anticipate G1 Therapeutics' stock price to reach $61.50 in the next year. This suggests a possible upside of 243.4% from the stock's current price. View analysts' price targets for G1 Therapeutics.

Has G1 Therapeutics been receiving favorable news coverage?

Headlines about GTHX stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. G1 Therapeutics earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutG1 Therapeutics.

Are investors shorting G1 Therapeutics?

G1 Therapeutics saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 2,800,000 shares, a drop of 16.9% from the April 15th total of 3,370,000 shares. Based on an average daily volume of 326,700 shares, the short-interest ratio is currently 8.6 days. Approximately 10.2% of the company's shares are short sold. View G1 Therapeutics' Current Options Chain.

Who are some of G1 Therapeutics' key competitors?

What other stocks do shareholders of G1 Therapeutics own?

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:
  • Dr. Mark A. Velleca, CEO, Pres & Director (Age 55)
  • Mr. James Stillman Hanson, Gen. Counsel (Age 47)
  • Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 59)
  • Mr. John Demaree, Chief Commercial Officer (Age 52)
  • Ms. Jennifer K. Moses, Chief Financial Officer (Age 44)

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Management Group LLP (9.86%), BlackRock Inc. (6.83%), JPMorgan Chase & Co. (4.49%), State Street Corp (3.64%), Geode Capital Management LLC (1.21%) and Deutsche Bank AG (1.15%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Cynthia Schwalm, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends for G1 Therapeutics.

Which major investors are selling G1 Therapeutics stock?

GTHX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Burrage Capital Management LLC, UBS Group AG, Rhenman & Partners Asset Management AB, Alps Advisors Inc., State Street Corp, Virtus ETF Advisers LLC, and Legal & General Group Plc. View insider buying and selling activity for G1 Therapeutics.

Which major investors are buying G1 Therapeutics stock?

GTHX stock was acquired by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Morgan Stanley, 361 Capital LLC, Two Sigma Investments LP, Federated Hermes Inc., Two Sigma Advisers LP, Geode Capital Management LLC, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, James S Hanson, and John Demaree. View insider buying and selling activity for G1 Therapeutics.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $17.91.

How big of a company is G1 Therapeutics?

G1 Therapeutics has a market capitalization of $675.92 million. The company earns $-122,450,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is www.g1therapeutics.com.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.